This post was originally published on this site
However, given the current focus on production and manufacturing industries to help drive the economy back to pre-pandemic levels, capital investments in the field of healthcare are likely to remain low in the near term.
With that in mind, we think the current price levels of healthcare stocks NovoCure Limited (NVCR), 10x Genomics, Inc. (TXG), GoodRx Holdings, Inc. (GDRX), and Doximity, Inc. (DOCS) look unsustainable, given the companies’ weak growth prospects. Therefore, these stocks are best avoided now.
